Aim To determine the efficacy and safety of pharmacogenomics (PGx)-guided
antidepressant prescribing in patients with depression through an umbrella review and …

Objective: In this review, the authors update the 2018 report of the American Psychiatric
Association Council of Research Workgroup on Biomarkers and Novel Treatments on …

Antidepressant outcomes in older adults with depression is poor, possibly because of
comorbidities such as cerebrovascular disease. Therefore, we leveraged multiple genome …

Depression is a common and highly disabling condition in older adults. It is a heterogenous
disorder and there is emerging evidence of a link between inflammation and depression in …

Pharmacogenomic (PGx) testing may increase the probability of remission and response in
patients with major depressive disorder (MDD) undergoing pharmacotherapy. Given the …

Abstract Purpose Combinatorial pharmacogenetic (PGx) panels intended to aid psychiatric
prescribing are available to clinicians. Here, we evaluated the documentation of PGx panel …

Introduction: Clinically important depressive symptoms that occur in adults over age 60 are
often termed late-life depression (LLD). LLD poses challenges for treating clinicians in both …

The term severe mental illness (SMI) encompasses those psychiatric disorders exerting the
highest clinical burden and socio-economic impact on the affected individuals and their …

Objectives The primary objective was to identify the proportion of patients who successfully
completed PGx testing. Secondary objectives included determining the proportion of …

Research into ageing covers opportunities and challenges posed by an older population,
and research to understand the ageing processes across the lifespan. The evidence base …